SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events - PACE-CME

SGLT inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

NOAC as possible treatment option in patients with AF after successful TAVI
NOAC as possible treatment option in patients with AF after successful TAVI
ESC 2021
NOAC as possible treatment option in patients with AF after successful TAVI
- Prof. Nicolas van Mieghem, MD, PhD
Surgery vs. stenting with asymptomatic critical carotid artery stenosis
Surgery vs. stenting with asymptomatic critical carotid artery stenosis
ESC 2021
Surgery vs. stenting with asymptomatic critical carotid artery stenosis
- Prof. Freek Verheugt, MD
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
ESC 2021
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
- Prof. Frank Ruschitzka, MD
CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD
CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD
ESC 2021
CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD
- Kevin Damman, MD, PhD